Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.

Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BWG, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JWF, Xylinas E, Hendricksen K; Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology.

Eur Urol Focus. 2018 Dec 14. pii: S2405-4569(18)30382-1. doi: 10.1016/j.euf.2018.12.002. [Epub ahead of print]

PMID:
30559065
2.

Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma.

Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Hendricksen K, Horenblas S, Jóźwiak K, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BW, Wit EM, Bex A.

Scand J Urol. 2018 Dec 11:1-8. doi: 10.1080/21681805.2018.1531057. [Epub ahead of print]

PMID:
30526184
3.

An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors.

Kuusk T, Donswijk ML, Valdés Olmos RA, De Bruijn RE, Brouwer OR, Hendricksen K, Horenblas S, Jóźwiak K, Prevoo W, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A.

EJNMMI Res. 2018 Dec 3;8(1):105. doi: 10.1186/s13550-018-0460-y.

4.

Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.

Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, Gontero P, Lam T, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Yuan Y, Zigeuner R, Babjuk M.

Eur Urol Focus. 2018 Nov 20. pii: S2405-4569(18)30337-7. doi: 10.1016/j.euf.2018.11.005. [Epub ahead of print] Review.

PMID:
30470647
5.

Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.

Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, van der Heijden MS, van der Hulst JB, Sanders J, Broeks A, Kerst JM, van der Noort V, Horenblas S, Bergman AM.

J Urol. 2018 Oct 12. pii: S0022-5347(18)43985-7. doi: 10.1016/j.juro.2018.10.007. [Epub ahead of print]

PMID:
30321552
6.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
7.

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, Verhoeven RHA, van Rhijn BWG.

Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31833. [Epub ahead of print]

PMID:
30155893
8.

Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?

Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid HA, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Dominguez-Escrig JL, Hernández V, Peyronnet B, Seisen T, Soukup V; European Association of Urology Guidelines Panel on Non–muscle-invasive Bladder Cancer.

Eur Urol Focus. 2018 Jul;4(4):525-528. doi: 10.1016/j.euf.2018.07.023. Epub 2018 Jul 27.

PMID:
30061076
9.

Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS.

Eur Urol. 2018 Nov;74(5):597-608. doi: 10.1016/j.eururo.2018.06.024. Epub 2018 Jul 13.

PMID:
30017405
10.

Prostate sparing cystectomy for bladder cancer: A two-center study.

Voskuilen CS, Fransen van de Putte EE, Pérez-Reggeti JI, van Werkhoven E, Mertens LS, van Rhijn BWG, Saad M, Bex A, Cathelineau X, van der Poel HG, Horenblas S, Sanchez-Salas R, Meijer RP.

Eur J Surg Oncol. 2018 Sep;44(9):1446-1452. doi: 10.1016/j.ejso.2018.05.032. Epub 2018 Jun 8.

PMID:
29929902
11.

Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors.

Bosschieter J, Hentschel A, Savci-Heijink CD, Patrick van der Voorn J, Rozendaal L, Vis AN, van Rhijn BWG, Lissenberg-Witte BI, Fransen van de Putte EE, van Moorselaar RJA, Nieuwenhuijzen JA.

Clin Genitourin Cancer. 2018 Oct;16(5):e985-e992. doi: 10.1016/j.clgc.2018.05.002. Epub 2018 May 11.

PMID:
29884516
12.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2018 Jun 7. doi: 10.1007/s00345-018-2361-0. [Epub ahead of print]

PMID:
29882105
13.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
14.

The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review.

Bosschieter J, Lutz C, Segerink LI, Vis AN, Zwarthoff EC, A van Moorselaar RJ, van Rhijn BW, Heymans MW, Jansma EP, Steenbergen RD, Nieuwenhuijzen JA.

Epigenomics. 2018 May;10(5):673-687. doi: 10.2217/epi-2017-0156. Epub 2018 Apr 25.

PMID:
29692199
15.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

PMID:
29672836
16.

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM.

Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12.

17.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
18.

Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer.

Mayr R, Fritsche HM, Zeman F, Reiffen M, Siebertz L, Niessen C, Pycha A, van Rhijn BWG, Burger M, Gierth M.

World J Urol. 2018 Aug;36(8):1201-1207. doi: 10.1007/s00345-018-2259-x. Epub 2018 Mar 8.

PMID:
29520591
19.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Review.

PMID:
29496372
20.

Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer.

Mayr R, Gierth M, Zeman F, Reiffen M, Seeger P, Wezel F, Pycha A, Comploj E, Bonatti M, Ritter M, van Rhijn BWG, Burger M, Bolenz C, Fritsche HM, Martini T.

J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):505-513. doi: 10.1002/jcsm.12279. Epub 2018 Feb 25.

21.

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A.

Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22.

PMID:
29473226
22.

Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016".

Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Sylvester RJ, Zigeuner R, Babjuk M.

Eur Urol Focus. 2018 Jan 20. pii: S2405-4569(18)30004-X. doi: 10.1016/j.euf.2018.01.003. [Epub ahead of print] Review.

PMID:
29366854
23.

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.

Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W; Collaborators.

J Urol. 2018 Jun;199(6):1452-1458. doi: 10.1016/j.juro.2017.12.062. Epub 2018 Jan 9.

PMID:
29329894
24.

Lymphatic Drainage from Renal Tumors In Vivo: A Prospective Sentinel Node Study Using SPECT/CT Imaging.

Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Grivas N, Hendricksen K, Horenblas S, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A.

J Urol. 2018 Jun;199(6):1426-1432. doi: 10.1016/j.juro.2017.11.112. Epub 2017 Dec 6.

PMID:
29223390
25.

Short-term outcome after cystectomy: comparison of early oral feeding in an enhanced recovery protocol and feeding using Bengmark nasojejunal tube.

Voskuilen CS, van de Putte EEF, der Hulst JB, van Werkhoven E, de Blok WM, van Rhijn BWG, Horenblas S, Meijer RP.

World J Urol. 2018 Feb;36(2):221-229. doi: 10.1007/s00345-017-2133-2. Epub 2017 Nov 22.

26.

Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.

Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Gontero P, Lam T, MacLennan S, Mostafid H, Palou J, van Rhijn BWG, Sylvester RJ, Zigeuner R, Shariat SF, Rouprêt M.

Eur Urol Focus. 2017 Nov 17. pii: S2405-4569(17)30236-5. doi: 10.1016/j.euf.2017.09.015. [Epub ahead of print] Review.

PMID:
29158169
27.

Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review.

Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, Maclennan S, N'dow J, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Mostafid H, van Rhijn BWG, Gontero P, Palou J, Shariat SF, Roupret M.

Eur Urol Focus. 2017 Nov 15. pii: S2405-4569(17)30240-7. doi: 10.1016/j.euf.2017.10.003. [Epub ahead of print] Review.

PMID:
29154042
28.

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG.

Urol Oncol. 2018 Sep;36(9):413-422. doi: 10.1016/j.urolonc.2017.10.014. Epub 2017 Nov 8. Review.

PMID:
29128420
29.

Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.

Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, Gontero P, Necchi A, Noon AP, van Rhijn BWG, Rink M, Roghmann F, Rouprêt M, Seiler R, Shariat SF, Qvick B, Babjuk M, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.

Eur Urol Focus. 2017 Oct 23. pii: S2405-4569(17)30206-7. doi: 10.1016/j.euf.2017.09.002. [Epub ahead of print]

PMID:
29074050
30.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.

Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, Shariat SF.

Eur Urol. 2018 Jan;73(1):111-122. doi: 10.1016/j.eururo.2017.07.036. Epub 2017 Sep 1. Review.

PMID:
28867446
31.

Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer.

Breyer J, Shalekenov S, Aziz A, van Rhijn BWG, Bründl J, Lausenmeyer E, Schäfer J, Denzinger S, Giedl C, Burger M, Hartmann A, Evert M, Otto W.

Bladder Cancer. 2017 Jul 27;3(3):173-180. doi: 10.3233/BLC-170103.

32.

Endo-Urological Techniques for Benign Uretero-Ileal Strictures Have Poor Efficacy and Affect Renal Function.

Fransen van de Putte EE, de Wall LL, van Werkhoven E, Heldeweg EA, Bex A, van der Poel HG, van Rhijn BWG, Horenblas S, Hendricksen K.

Urol Int. 2018;100(1):18-24. doi: 10.1159/000475508. Epub 2017 Aug 18.

PMID:
28817820
33.

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, Chandrananda D, Marass F, van den Broek D, Neal DE, Gnanapragasam VJ, Forshew T, van Rhijn BW, Massie CE, Rosenfeld N, van der Heijden MS.

Sci Rep. 2017 Jul 17;7(1):5554. doi: 10.1038/s41598-017-05623-3.

34.

FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

van de Putte EEF, Vegt E, Mertens LS, Bruining A, Hendricksen K, van der Heijden MS, Horenblas S, van Rhijn BWG.

Int Urol Nephrol. 2017 Sep;49(9):1585-1591. doi: 10.1007/s11255-017-1637-4. Epub 2017 Jul 3.

PMID:
28674853
35.

Dose dense MVAC prior to radical cystectomy: a real-world experience.

Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshmand S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W.

World J Urol. 2017 Nov;35(11):1729-1736. doi: 10.1007/s00345-017-2065-x. Epub 2017 Jun 17.

PMID:
28625005
36.

Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.

Bosschieter J, Vis AN, van der Poel HG, Moonen LM, Horenblas S, van Rhijn BWG, Pieters BR, Nieuwenhuijzen JA, Hendricksen K.

Eur Urol. 2018 Sep;74(3):369-375. doi: 10.1016/j.eururo.2017.05.054. Epub 2017 Jun 12.

PMID:
28619396
37.

Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.

Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, Compérat E, Gontero P, Lam T, MacLennan S, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Yuan Y, Zigeuner R.

Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28. Review.

PMID:
28457661
38.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
39.

Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.

Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, Hermanns T, Fleshner NE, van Rhijn BW, van der Kwast TH, Zlotta AR, Bapat B.

Transl Oncol. 2017 Apr;10(2):168-177. doi: 10.1016/j.tranon.2017.01.001. Epub 2017 Feb 3.

40.

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Otto W, Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A.

Int Urol Nephrol. 2017 Mar;49(3):431-437. doi: 10.1007/s11255-016-1491-9. Epub 2016 Dec 29.

PMID:
28035618
41.

Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

Hermans TJ, Fransen van de Putte EE, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, de Wit R, Beerepoot LV, Verhoeven RH, van Rhijn BW.

Eur J Cancer. 2016 Dec;69:1-8. doi: 10.1016/j.ejca.2016.09.015. Epub 2016 Oct 27.

PMID:
27814469
42.

Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.

Downes MR, Weening B, van Rhijn BW, Have CL, Treurniet KM, van der Kwast TH.

Histopathology. 2017 Jan;70(2):281-289. doi: 10.1111/his.13063. Epub 2016 Oct 28.

PMID:
27530957
43.

Genetics and biological markers in urachal cancer.

Behrendt MA, van Rhijn BW.

Transl Androl Urol. 2016 Oct;5(5):655-661. Review.

44.

Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.

Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.

J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017. Epub 2016 Jun 14.

PMID:
27312316
45.

Extended pelvic lymph node dissection at radical cystectomy for bladder cancer improves survival: Results of a nationwide population-based study.

Hermans TJ, Fransen van de Putte EE, Horenblas S, van Rhijn BW, Verhoeven RH.

Int J Urol. 2016 Dec;23(12):1043-1044. doi: 10.1111/iju.13227. Epub 2016 Oct 4. No abstract available.

46.

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA.

Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Review.

PMID:
27641313
47.

Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease.

van Rhijn BW, Burger M.

Nat Rev Urol. 2016 Oct;13(10):570-1. doi: 10.1038/nrurol.2016.165. Epub 2016 Aug 31. Review. No abstract available.

PMID:
27578042
48.

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer.

van Kessel KE, de Haan LM, Fransen van de Putte EE, van Rhijn BW, de Wit R, van der Heijden MS, Zwarthoff EC, Boormans JL.

Bladder Cancer. 2016 Jul 27;2(3):351-360.

49.

Variations in pelvic lymph node dissection in invasive bladder cancer: A Dutch nationwide population-based study during centralization of care.

Hermans TJ, Fransen van de Putte EE, Fossion LM, Werkhoven EV, Verhoeven RH, van Rhijn BW, Horenblas S.

Urol Oncol. 2016 Dec;34(12):532.e7-532.e12. doi: 10.1016/j.urolonc.2016.06.018. Epub 2016 Aug 2.

PMID:
27491835
50.

Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.

Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Rouprêt M.

Eur Urol. 2016 Dec;70(6):1052-1068. doi: 10.1016/j.eururo.2016.07.014. Epub 2016 Jul 28. Review.

PMID:
27477528

Supplemental Content

Loading ...
Support Center